Statistical Designing and Characterization of Valsartan Oral Disintegrating Tablet

Iizhar Ahmed Syed¹, Chandrasekhar Patro², Asim Muhammed Alshanberi³, Shakeel Ahmed Ansari⁴,*

¹Department of Pharmaceutics, Nethaji Institute of Pharmaceutical Sciences, Warangal, India
²Department of Pharmaceutics, School of Pharmacy and Life Sciences, Centurion University of Technology and Management, India
³Department of Community Medicine and Pilgrims Health Care, Umm Alqura University, Makkah, Saudi Arabia
⁴Department of Biochemistry, School of Medicine, Batterjee Medical College for Sciences and Technology, Jeddah, Saudi Arabia

Received February 24, 2021; Revised May 26, 2021; Accepted June 6, 2021

Cite This Paper in the following Citation Styles
(a): [1] Iizhar Ahmed Syed, Chandrasekhar Patro, Asim Muhammed Alshanberi, Shakeel Ahmed Ansari , “Statistical Designing and Characterization of Valsartan Oral Disintegrating Tablet,” Advances in Pharmacology and Pharmacy, Vol. 9, No. 3, pp. 33 - 44, 2021. DOI: 10.13189/app.2021.090301.
(b): Iizhar Ahmed Syed, Chandrasekhar Patro, Asim Muhammed Alshanberi, Shakeel Ahmed Ansari (2021). Statistical Designing and Characterization of Valsartan Oral Disintegrating Tablet. Advances in Pharmacology and Pharmacy, 9(3), 33 - 44. DOI: 10.13189/app.2021.090301.

Copyright©2021 by authors, all rights reserved. Authors agree that this article remains permanently open access under the terms of the Creative Commons Attribution License 4.0 International License

Abstract The present study involves the formulation and characterization of valsartan (VT) oral disintegrating tablets by using crospovidone (CP) and Hibiscus rosasinensis (HRS) mucilage as complexing agent. Valsartan (VT), anti-hypertensive drug (class II) is an orally active non-peptide triazole-derived antagonist of angiotensin II. The direct compression method was used to obtain 13 such formulations, and the tablets obtained were evaluated for drug content, hardness, friability (FT), disintegration time (DT) and dissolution rate. A significant increase in the dissolution rate of VT was obtained. FTIR and DSC studies showed no interaction between the drug and excipients. The amount of CP (X₁) and amount to HRS mucilage (X₂) is selected for 3² factorial designs. The DT (Y₁), FT (Y₂) and % drug released at 25 min (Y₃) interval were taken as the response variables. X₁ and X₂ represents the result of changing the variable at a time from low level to high level. The interaction terms (X₁X₂, X₁², X₂², X₁X₂², and X₁²X₂) exhibited that Y₁, Y₂ and Y₃ had changed simultaneously (as analyzed by Design expert software 8 version). The contour and 3D plots revealed that there is an effect of X₁ and X₂ with the interaction on Y₁, Y₂ and Y₃. F₂ formulation exhibited minimum errors with CP and HRS in response to dependable variables which is concluded as best formulation.

Keywords Valsartan, Hibiscus rosasinensis, Optimization, Oral Disintegrating Tablets

1. Introduction

New technologies are revolutionizing the drug discovery and the novel formulation development in pharmaceutical industries. In this regard, novel concepts of drug delivery systems have much therapeutic benefit, which may improve the efficacy and duration of drug activity. Moreover, such systems increase the patient compliance by reducing the dosing frequency, provide easy routes of drug administration and improve site-specific drug delivery to reduce adverse effects [1,2]. Nearly, 95% of new active pharmaceutical ingredient drug demonstrates low and variable oral bioavailability due to their poor aqueous solubility at physiological pH, resulting in a lower dissolution rate. The drug which shows low solubility and high permeability come under class II according to Biopharmaceutics Classification System (BCS). Hence, it has been a tough challenge for the pharmaceutical scientists to formulate oral disintegrating tablet for poorly soluble drugs as it requires enhancement in the dissolution rates [3-5].The techniques that have been generally employed for enhancing the solubility of drugs include micronisation and cyclodextrin-complexation which involves the use of surfactants, solubilizers and super disintegrants. They
improve the solubility of class-II drugs by increasing the dissolution rate and bioavailability significantly [6]. Nevertheless, complexation with cyclodextrin and using super disintegrants such as crospovidone and sodium starch glycolate are industrial methods that are largely used to enhance the dissolution rate of poorly soluble drugs during the formulation development. The super disintegrants are added to facilitate drug release and improve the dissolution rate [7-9].

*Hibiscus rosasinensis* mucilage acts as a super disintegrant. It is chemically composed of cyclopropanoids, methyl sterculate, methyl-2-hydroxyl sterculate, 2-hydroxyl sterculate malvate and β-rosasterol. Its leaf contains carotene, protein, fat, carbohydrate, fibers, calcium and phosphorus, while the mucilage constitutes L-rhamnose, D-galactose, D-galactouronic acid and D-glucuronic acid [10,11]. Moreover, crospovidone (crosslinked polyvinyl N-pyrolidone) is used in combination with active ingredients in medications and dietary supplements for allowing the absorption of active drug [12].

Response surface methodology is a widely employed technique that is used for formulating and optimizing drug formulation with suitable experimental design [13]. Valsartan is widely prescribed anti-hypertensive drug that possesses poor aqueous solubility and low dissolution rate [14]. Hence, this study investigates the formulation and optimization of valsartan as oral disintegrating tablets by crospovidone and *hibiscus rosasinensis* mucilage as complexing agent by response surface methodology technique.

## 2. Materials and Methods

### 2.1. Materials

Valsartan was obtained from Hetero Drugs Private Limited, India. *Hibiscus rosasinensis* mucilage and crospovidone were procured from Natco Pharma Limited, India. Free trial version 8 Design expert software was used in statistical designing of drugs. All reagents were prepared in double distilled water with chemicals of analytical grade.

### 2.2. Extraction of HRS Mucilage

The matured leaves of HRS were collected, followed by washing and drying at 37°C for 1 day. They were then crushed and soaked in warm water for 2-3 h and heated at 80-90°C for 30-45 min. The mixture obtained was kept for 1 day in order to bring out the complete release of water soluble mucilage (i.e. polysaccharide) into the solvent. The mucilage was then extracted by using a cheese cloth bag to remove the mark for obtaining a concentrated viscous solution. Acetone was added to the concentrated viscous solution with constant stirring. The gel like precipitate was formed and then separated by filtration. The precipitate was washed thrice with acetone. The resulting precipitate was dried in oven at 40±1°C followed by air drying overnight. The compact mass was collected, grounded, passed through a sieve≠50 and stored in a desiccator until further use. The dry powder was considered as water soluble polysaccharide mucilage for pharmaceutical use [11].

### 2.3. Formulation of Valsartan Tablets

The optimization of Valsartan tablets was performed according to 3² factorial design. It includes crospovidone (CP) as 2.5%, 5% and 7.5% and *Hibiscus rosasinensis* (HRS) mucilage as 5%, 10% and 15% of the total weight of the tablet, and are considered as independent variables and dependent variables, respectively. Disintegration time (DT), Friability (%) and Cumulative Drug Release (%) at 25 min were dependent variables. Other excipient includes magnesium stearate (2 mg), aerosil (2 mg), talc (2 mg) and flavor (6 mg). Nine tablet formulations were prepared by a direct compression technique. The weight of tablet was 200 mg with 50 tablets batch size (Table 1).

### 2.4. Experimental Design

The amount of crospovidone (X₁) and HRS mucilage (X₂) were selected as independent variables, and were studied at 3 levels each. The central point was performed in triplicates. All other formulations and processing variables were kept invariant throughout the study. 13 experimental runs were made in the study (Table 1 and Table 2). Their factor combination and translation of the coded level to the experimental units were employed during the study. Disintegration time (Y₁), friability (Y₂) and cumulative drug released at 25 minutes (Y₃) was taken as response variables.

### 2.5. Evaluation of the Oral Disintegrating Tablets (ODT)

10 tablets from each formulation were taken for measurement of diameter and crown thickness with Vernier caliper, and an average of ten determinations was carried out. Hardness of the prepared oral disintegrating tablets (ODT) was evaluated by using hardness tester. Weight variation test was performed for 20 tablets from each batch and average values were calculated. Friability of the prepared ODT was determined by weighing 10 tablets, and placing in a friability tester (Roche friabilator, Pharma Labs, Ahmedabad, India), which was rotated for 4 min at 25 rpm. After the de-dusting, the weight of the tablets was recorded and the % friability was calculated. Disintegration test was performed for the prepared ODT by using single unit disintegration test apparatus.
(Paramount) by employing phosphate buffer (pH 6.8) as test fluid. The disintegration time was noted for all the formulations. The drug content uniformity was also performed by crushing ten ODT tablets in a glass mortar and pestle. An accurately weighed quantity of powder equivalent to 20 mg of valsartan was taken into 100 ml volumetric flask, dissolved in the assay buffer and the solution was filtered through Whatman filter paper no. 41. The filtrate was collected and suitably diluted with a phosphate buffer of pH 6.8 and assayed for valsartan at 250 nm. The flow properties such as angle of repose, bulk density tapped density, Hausner’s ratio and Carr’s index were also evaluated.

The wetting time and water absorption ratio were also evaluated for the prepared valsartan tablets. The measurement of wetting time was done by using a simple procedure. Five circular tissue papers of 10 cm diameter were placed in a petri dish with a 10 cm diameter. About 10 mm of water containing a water-soluble dye was added to the petri dish. At room temperature, F2 formulation tablets were kept carefully on the surface of tissue paper in a petri dish. Time taken by water molecules to reach the upper surface of the F2 formulation until measured it gets wet completely. The analysis was carried out (n = 20), and the mean value was calculated.

The water absorption ratio, R, was determined according to the following equation:

\[ R = 100(W_a - W_b)/W_a \]

Where, \( W_a \) and \( W_b \) are the weight before and after water absorption, respectively.

### 2.6. In-vitro Drug Release Studies

**In vitro** dissolution studies, the prepared ODT were conducted for a period of 25 min using six station USP XXII type 2 apparatus (Lab India Disso 2000 system, India) at 37±0.5°C at 50 rpm. The dissolution studies were carried out in triplicate for 25 min in 900 ml potassium phosphate buffer (pH 6.8) at different time intervals. Sample (5 ml) was withdrawn with a pre-filter and replaced with the same buffer to maintain sink conditions. After suitable dilution, samples were analyzed at 250 nm using UV spectrophotometer (SL-150, Elico, India). The amount of drug presented in the samples was calculated with the help of appropriate calibration curves constructed from reference standards. The physical changes of the formulations were observed throughout the drug release studies.

### 2.7. Characterization of Release Data

The description of dissolution profiles was attempted using different release models [15-16]. The data was evaluated according to the following equations:-

**Zero order:**

\[ Mt = Mo + Kot \]

**First order:**

\[ \ln Mt = \ln M_0 + K1t \]

Where \( M_t \) is the amount of drug dissolved in time \( t \), \( M_0 \) is the initial amount of drug, \( K_1 \) is the first order release constant and \( K_0 \) is the zero-order release constant.

### 2.8. FTIR Study

FTIR spectra (FTIR Spectrum RX1, Perkin Elmer Ltd, Switzerland) were obtained by scanning the sample in KBr discs. The samples of pure valsartan and ODT tablets were scanned individually.

### 2.9. DSC Study

DSC scan was performed for the pure drug valsartan and the ODT tablets F2 by DSC-827e, Mettler, Toledo-Inc, 1900, USA. The aluminum pans were used in the experiment and the empty pan were also sealed to be used as references. The temperature was calibrated with indium as standard. The scanning rate of samples was from 50-300°C at 10°C/min.

### 3. Results and Discussion

The current study reveals the optimization procedure of preparing a series of ODT tablet formulations for valsartan by varying the concentrations of formulation ingredients in a systematic manner. This procedure was simplified by applying factorial designs and fitting into an empirical polynomial equation to the experimental results. These formulations were then assessed for appearance, taste, hardness, dissolution rate and other stability studies. Based on these results, F2 formulation was predicted to be optimal. The translation code for the prepared ODT has been shown in Table 1 and 2. The data for friability %, disintegration time and cumulative percentage drug release (response variable) is shown in Table 3. Moreover, Table 4 exhibited the composition of the optimized formulation of valsartan ODT, the predicted and experimental values of response variables. Valsartan tablets formulated by employing HRS mucilage weighed 21.25 mg (Table 5). F2 formulation disintegrated within 16 sec and exhibited least friability data (Table 3). Table 6 depicts good flow properties for F2 formulations, the post-compression parameters, and measured values of wetting time and water absorption ratio. Fig 7 also shows the dispersion and wetting time for F2 formulation. The hardness of the tablets was in the range 3.5-4.5 kg/cm². However, weight loss in the friability test was less than 0.75 % in all the cases. It should be noted that the valsartan content of the tablets prepared was within 99.85±0.33 %.
3.1. *In-vitro* Drug Release Studies

Drug release studies were carried out for 25 min in neutral pH buffer. The amount of valsartan released from the ODT was observed and calculated. The percentage of drug released from all the designed formulations is shown in Table 5. Visual observations revealed that the tablets appeared swollen almost from the beginning. CP and HRS showed rapid hydration and forms loose channels for the passage of drug VT. The dissolution study revealed that all the tablets were completely eroded. It might be attributed to the formation of a very loose porous mass with CP and HRS in 1:3 ratio. This step leads to the initiation of drug VT to disperse readily and rapidly. Hence, the dissolution rate may be enhanced by complexation [1,12].

3.2. Characterization of Release Data

The dissolution mechanism was characterized by using different release models. The correlation co-efficient \( r^2 \) for zero order kinetics and first order kinetics were interpreted for all the formulations. The data proves that the VT tablets follow first order release kinetics with higher \( r^2 \) values and rapid release of drug due to the presence of complexing of CP: HRS mucilage.

### Table 1. Experimental Design carried out for ODT of Valsartan with CP and HRS

| Formulation | Coded factor levels |
|-------------|---------------------|
|             | X1 | X2 |
| F 1         | -1 | -1 |
| F 2         | 0  | -1 |
| F 3         | 1  | -1 |
| F 4         | -1 | 0  |
| F 5         | 0  | 0  |
| F 6         | 1  | 0  |
| F 7         | -1 | 1  |
| F 8         | 0  | 1  |
| F 9         | 1  | 1  |

### Table 2. Translation of Coded levels in Actual units

| Coded Level | -1 | 0 | +1 |
|-------------|----|---|----|
| X1: Crospovidone (%) | 2.5 | 5 | 7.5 |
| X2: H. rosasiniensis mucilage (%) | 5 | 10 | 15 |

### Table 3. Response Variables (Y1, Y2 and Y3) obtained from various Trial Formulations

| Trial Run | Crospovidone (mg) \( (X_1) \) | H.R Mucilage (mg) \( (X_2) \) | Disintegration Time (sec) \( (Y_1) \) | Friability % \( (Y_2) \) | Cumulative % Drug Released \( (Y_3) \) |
|-----------|-------------------------------|-------------------------------|--------------------------------|------------------|-------------------------------|
| F1        | 5                             | 10                            | 24±0.01                        | 0.51±0.01        | 96.16±1.82                    |
| F2        | 10                            | 10                            | 16±0.04                        | 0.45±0.02        | 97.02±2.37                    |
| F3        | 15                            | 10                            | 12±0.01                        | 0.31±0.04        | 99.01±1.73                    |
| F4        | 5                             | 20                            | 15±0.02                        | 0.37±0.05        | 96.50±1.54                    |
| F5        | 10                            | 20                            | 13±0.02                        | 0.35±0.02        | 98.77±2.27                    |
| F6        | 15                            | 20                            | 10±0.01                        | 0.25±0.01        | 99.81±1.55                    |
| F7        | 5                             | 30                            | 17±0.03                        | 0.41±0.01        | 96.58±1.26                    |
| F8        | 10                            | 30                            | 19±0.01                        | 0.49±0.02        | 96.16±2.89                    |
| F9        | 15                            | 30                            | 15±0.05                        | 0.45±0.03        | 97.62±1.25                    |
Table 4. Composition of the optimized formulation of valsartan ODT, the predicted and experimental values of response variables

| No. | Crospovidone (mg) | H. rosasinensis Mucilage (mg) | Disintegration time | Cumulative % drug released | % Friability | Cumulative % drug released | Disintegration time | % Friability | Cumulative % drug released | Disintegration time | % Friability | Cumulative % drug released | Disintegration time | % Friability | Cumulative % drug released | Disintegration time | % Friability | Cumulative % drug released | Disintegration time | % Friability | Cumulative % drug released |
|-----|------------------|-----------------------------|---------------------|---------------------------|-------------|---------------------------|---------------------|-------------|---------------------------|---------------------|-------------|---------------------------|---------------------|-------------|---------------------------|---------------------|-------------|---------------------------|---------------------|-------------|---------------------------|
| F1  | 14.00            | 18.00                       | 10.789              | 99.362                    | 0.244       | 0.255                     | 10.575              | 0.266       | 100.107                   | 10.772              | 0.288       | 99.391                    | 10.365              | 0.293       | 99.986                    | 10.552              | 0.291       | 100.053                   | 11.081              | 0.285       | 99.864                    | 10.92               | 0.275       | 99.144                    | 10.92               | 0.279       | 99.986                    |
| F2  | 14.75            | 21.25                       | 10.754              | 99.695                    | 0.255       | 0.266                     | 10.66               | 0.011       | 100.254                   | 10.637              | 0.032       | 99.702                    | 10.94               | 0.116       | 99.853                    | 10.998              | 0.126       | 99.737                    | 10.777              | 0.031       | 99.485                    |
| F3  | 14.28            | 15.58                       | 10.754              | 99.695                    | 0.255       | 0.266                     | 10.66               | 0.011       | 100.254                   | 10.637              | 0.032       | 99.702                    | 10.94               | 0.116       | 99.853                    | 10.998              | 0.126       | 99.737                    | 10.777              | 0.031       | 99.485                    |
| F4  | 14.12            | 17.25                       | 10.754              | 99.695                    | 0.255       | 0.266                     | 10.66               | 0.011       | 100.254                   | 10.637              | 0.032       | 99.702                    | 10.94               | 0.116       | 99.853                    | 10.998              | 0.126       | 99.737                    | 10.777              | 0.031       | 99.485                    |
| F5  | 14.75            | 12.75                       | 10.754              | 99.695                    | 0.255       | 0.266                     | 10.66               | 0.011       | 100.254                   | 10.637              | 0.032       | 99.702                    | 10.94               | 0.116       | 99.853                    | 10.998              | 0.126       | 99.737                    | 10.777              | 0.031       | 99.485                    |
| F6  | 14.00            | 20.00                       | 10.754              | 99.695                    | 0.255       | 0.266                     | 10.66               | 0.011       | 100.254                   | 10.637              | 0.032       | 99.702                    | 10.94               | 0.116       | 99.853                    | 10.998              | 0.126       | 99.737                    | 10.777              | 0.031       | 99.485                    |
| F7  | 14.02            | 15.88                       | 10.754              | 99.695                    | 0.255       | 0.266                     | 10.66               | 0.011       | 100.254                   | 10.637              | 0.032       | 99.702                    | 10.94               | 0.116       | 99.853                    | 10.998              | 0.126       | 99.737                    | 10.777              | 0.031       | 99.485                    |
| F8  | 14.64            | 21.63                       | 10.754              | 99.695                    | 0.255       | 0.266                     | 10.66               | 0.011       | 100.254                   | 10.637              | 0.032       | 99.702                    | 10.94               | 0.116       | 99.853                    | 10.998              | 0.126       | 99.737                    | 10.777              | 0.031       | 99.485                    |
| F9  | 14.68            | 21.73                       | 10.754              | 99.695                    | 0.255       | 0.266                     | 10.66               | 0.011       | 100.254                   | 10.637              | 0.032       | 99.702                    | 10.94               | 0.116       | 99.853                    | 10.998              | 0.126       | 99.737                    | 10.777              | 0.031       | 99.485                    |

Table 5. Optimized formulation of valsartan as ODT (F<sub>2</sub>)

| Composition       | Amount (mg) |
|-------------------|-------------|
| Valsartan         | 80          |
| Pearlitol SD 100  | 48          |
| Crospovidone      | 14.75       |
| Hibiscus rosasinensis mucilage | 21.25 |
| Sorbitol          | 20          |
| Other excipients  | 12          |
| Aspartame         | 4           |

3.3. Optimization of Valsartan ODT

The optimization of valsartan ODT formulation was performed by Design Expert Software 8 version. Response surface methodology was used for the development and optimization of ODT [17-19]. Different steps involved in it include experimental design, regression analysis, constraint optimization and validation. Polynomial models including interaction and quadratic terms were generated for all the response variables using multiple linear regression analysis (MLRA) approach. The general form of the MLRA model is represented by the following equation:

\[ Y = \beta_0 + \beta_1 X_1 + \beta_2 X_2 + \beta_3 X_1 X_2 + \beta_4 X_1^2 + \beta_5 X_2^2 + \beta_6 X_1 X_2^2 \]

\[ \beta_0 \] is the intercept representing the arithmetic average of all quantitative outcomes of 9 runs; \( \beta_1 \) to \( \beta_7 \) are the coefficients computed from the observed experimental response values of \( Y \), and \( X_1 \) and \( X_2 \) are the coded levels of the independent variable(s). The terms \( X_1 X_2 \) and \( X_i^2 \) (i = 1 to 2) represent the interaction and quadratic terms, respectively. Two dimensional contour plots and three-dimensional response surface plots were constructed (Fig 1 to 6). Mathematical relationships in the form of a polynomial equation for the measured response
38 Statistical Designing and Characterization of Valsartan Oral Disintegrating Tablet

disintegration time, % friability and cumulative % drug released at 25 minutes were taken as the response variables. The polynomial equation relating to the different response and the independent variable is given below [20]:

\[
Y_1 (\text{Disintegration time}) = +13.52 - 2.50X_1 + 1.50X_2 - 2.50X_1^2 - 1.00X_2^2 \\
Y_2 (% \text{ Friability}) = +0.33 - 0.060X_1 + 0.020X_2 + 0.060X_1X_2 - 0.032X_1^2 + 0.13X_2^2 \\
Y_3 (\text{Cumulative % drug released}) = +98.09 + 1.66X_1 - 0.43X_2 - 0.45X_1X_2 + 0.34X_1^2 - 1.22X_2^2 + 0.19X_1^2X_2 - 0.68X_1X_2^2
\]

\text{Eq}(1) \quad \text{Eq}(2) \quad \text{Eq}(3)

3.4. Two Dimensional Contour Plots and Three-Dimensional Response Surface Plots

Fig 1 and 2 showed the effect of crospovidone (X_1) and HRS mucilage (X_2) on disintegration time (sec). It was observed that Y1 (disintegration time) decreases with the increase in concentrations of both independent variables; however, after a certain level of concentration, DT increases. It might be attributed to the network formation of wetted particles (with HRS mucilage) of the independent variables. Fig 3 and 4 showed the effect of crospovidone (X_1) and HRS mucilage (X_2) on friability. It indicates that the friability decreases by increasing the concentrations of both independent variables. It is also observed that the friability is decreased by increasing the concentration of HRS mucilage. Fig 5 and 6 showed the effect of crospovidone (X_1) and HRS mucilage (X_2) on cumulative % drug release in 25 min. It was observed that the percentage of drug release was increased by increasing the concentration of HRS mucilage.

3.5. Validation of Response Surface Methodology

Results for Valsartan ODT Formulation

The formulations corresponding to these checkpoints were prepared and evaluated for various response properties. Subsequently, the resultant experimental data of response properties were quantitatively compared with that of their predicted values. Table 4 showed the predicted and experimental values. F_2 formulation exhibited the predicted and experimental value of disintegration time, the percentage of friability and cumulative % drug release with least percentage error among all the formulations. Hence, F_2 formulation was chosen as the optimized ODT of valsartan with CP and HRS mucilage.

Table 6. Flow Properties and Post-compression parameters of the optimized formulation (F_2)

| Properties                                      | Optimized Formulation (F_2) |
|------------------------------------------------|-----------------------------|
| Angle of Repose (°)                             | 22.15                       |
| Bulk density                                    | 0.471                       |
| Tapped density                                  | 0.576                       |
| Carr’s Compressibility Index                    | 18.23                       |
| Hausner’s Ratio                                 | 1.192                       |
| Parameters Value                                | Value                       |
| Wetting time (sec)**                            | 8                           |
| Water Absorption ratio (%)**                    | 91.14±0.23                  |
| Weight variation (%)***                         | 0.42                        |
| Hardness*                                       | 3.1±0.37                    |
| Thickness(mm) *                                 | 3.1±0.11                    |
| Content uniformity (%)#                         | 99.81±0.48                  |
| Average weight**(mg)                            | 199.77                      |

* Each value was an average of six determinations
** Each value was an average of three determinations
# Result of one batch, n=20
Figure 1. Contour plot showing the effect of crospovidone ($X_1$) and HRS Mucilage ($X_2$) on Disintegration time (sec).

Figure 2. Response surface plot showing the effect of Crospovidone ($X_1$) and HRS mucilage ($X_2$) on Disintegration time (sec).
Figure 3. Contour plot showing the effect of Crospovidone ($X_1$) and HRS mucilage ($X_2$) on % Friability

Figure 4. Response surface plot showing the effect of crospovidone ($X_1$) and HRS mucilage ($X_2$) on % Friability
Figure 5. Contour Plot Showing Effect of Crospovidone ($X_1$) and HRS mucilage ($X_2$) on % drug release in 25 min

Figure 6. Response surface plot showing effect of Crospovidone ($X_1$) and HRS mucilage ($X_2$) on % drug released in 25 min
3.6. FTIR Studies

FTIR spectra revealed the presence of different functional groups in the compound (Fig 8). The characteristic absorption band was observed in 3610.28 cm\(^{-1}\) (due to C-H stretching of alkane), 1198.26 cm\(^{-1}\) and 1019.96 cm\(^{-1}\) (C-N vibration of aromatic tertiary amine), 1153.52 cm\(^{-1}\) (due to C=O stretching of acyclic saturated) and 1426.59 cm\(^{-1}\) (due to N-H group of aromatic secondary amine). The result suggested no chemical interaction between the drug and formulation which was confirmed due to disappearance of any characteristics peaks. The presence of peaks within the expected range confirmed that the materials utilized in drug formulation was unaffected thereby exhibiting no interactions.

3.7. DSC Studies

DSC thermogram for the pure drug valsartan exhibited sharp endotherm at 106.9°C which corresponds to its melting point (Fig 9a). The melting endothermic peaks of valsartan in the formulation are almost nearer and these peaks are the strong evidences of inclusion of drug into HRS mucilage cavity. Hence, for the mucilage complex and the intensity of the valsartan (F2 formulation) melting endotherm peaks had decreased (102.1°C) as shown in Fig 8b and another peak at 179.35°C which may be attributed to the presence of excipients in the physical mixture. The decreased and broadened peaks indicated complete amorphous state. These results concluded that interaction did not occur between the drug and excipients used in the study.
4. Conclusions

ODT of Valsartan was developed successfully by response surface methodology based on $3^2$ factorial designs. Lower levels of CP and higher levels of HRS gave high disintegration time ($Y_1$) with low friability % ($Y_2$). It was also observed that there was an increase in the valsartan release with the combination of CP with HRS. $F_2$ formulation exhibiting minimum errors with CP and HRS in response to dependable variables was optimized as best formulation. FTIR and DSC studies show no interaction between the drug and the excipients.

Abbreviations

VT: Valsartan  
CP: Crospovidone  
HRS: *Hibiscus rosasinensis*  
ODT: Oral disintegrating tablets

Acknowledgements

The authors are grateful to Hetero Drugs Private Limited, Hyderabad, India and Natco Pharma Limited, Hyderabad, India for providing valsartan, HRS mucilage and Crospovidone.

Conflict of Interest

The authors declare no conflict of interest.
**Author Contributions**

IAA: Basic ideas of the research, Application of data in Software and preparation of manuscript; CSP: Making HRS mucilage and different batch of tablets; SAA: Interpretation of the data generated from software and initial draft of the manuscript; AMA: Final draft of the manuscript and critical suggestion in revision stage.

**REFERENCES**

[1] Pierre H, Matthias S, Rosa M. Fast disintegrating oral dosage form. US Patent 1998; 6,083,531.

[2] Neduri K, Bontha VK, Vemula SK. Different techniques to enhance the dissolution rate of losartan: formulation and evaluation. Asian Journal of Pharmaceutical and Clinical Research, 2013; 56-60.

[3] Leidig M, Bambauer R, Kirchertz EJ, Szaba T, Handrock R, Leinung D. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis. Clinical Nephrology, 2008; 425-32.

[4] Buxton ILO. Principles of prescription order writing and patient compliance. In: Brunton LL, Lazo JS, Parker KL., editors. Goodman & Gilman’s. The pharmacological basis of therapeutics. 11th edition, New York: Mc GrawHill; 2006. pg 1777.

[5] Baunhakel M, Muller U, Bohm M. Valsartan improves symptoms and quality of life in patients with chronic heart failure. MMW Fortschr Medizin, 2008; 48-53.

[6] Jain CP, Naruka PS. Formulation and evaluation of fast dissolving tablets of valsartan. International Journal of Pharmacy and Pharma Science, 2009; 226-232.

[7] Avulapati S, Roy AK, Shashidhar KR, Ugendar RT. Formulation and evaluation of taste masked and fast disintegrating losartan potassium tablets. International Journal of Drug Development and Research, 2011; 45-51.

[8] Swathy RA, Sunil R, Allenki V, Ahmed SA. Formulation and in vitro evaluation of gastro retentive based micro beads of valsartan by gelation technique. International Journal of Farmacia, 2015;1: 48-60.

[9] Chourasiya V, Bohrey S, Pandey A. Formulation, optimization, characterization and in-vitro drug release kinetics of atenolol loaded PLGA nanoparticles using 33 factorial design for oral delivery. Materials Discovery, 2016; 1-13.

[10] Jadupati M, Nayak AK, Goswami S. Use of response surface methodology in the formulation and optimization of bisoprolol fumarate matrix tablets for sustained drug release. ISRN Pharmaceutics, 2012; 1-11.

[11] Prabhu KH, Shaista O, Rajanna SG & Pranesh KP. Formulation and evaluation of mouth disintegrating tablets of feptomidine by using Hibiscus rosasimensis mucilage and treated agar. International Journal of Research in Ayurveda and Pharmacy, 2010; 497-05.

[12] Shaddy SM, Arnold MA, Shilo K, Frankel WL, Harzman AE, Stanich PP, Singhi AD, Yearsley MM, Arnold CA. Crospovidone and microcrystalline cellulose: A novel description of pharmaceutical fillers in the gastrointestinal tract. American Journal of Surgery and Pathology, 2017; 564-69.

[13] Srikanth MV, Nali SR, Songa AS, Battu JR, Venkata RMK. Statistical design and evaluation of a propranolol HCl gastric floating tablet. Acta Pharmaceutica Sinica B, 2012; 60-9

[14] Husseiny RA, Lila ASA, Abdallah MH, El-ghamry HA. Fast disintegrating tablet of valsartan for the treatment of pediatric hypertension: In vitro and in vivo evaluation. Journal of Drug Delivery Science and Technology, 2018; 194-200.

[15] Izzhar SA., Ismail SA, Satar R, Ansari SA. In vitro assessment of pharmaceutical potential of ethosomes entrapped with terbinaine hydrochloride. Journal of Advanced Research, 2016; 7: 453-61.

[16] Omkar AP, Indrajert SP, Rahul UM, Dheeraj SR, Mangesh AB, Somnath DB. Formulation optimization and evaluation of cefdinir nanosuspension using 23factorial design. Journal of Research in Pharmacy, 2016; 7: 453-61.

[17] Howida KI, Doaa AES. Valsartan orodispersible tablets: Formulation, in vitro/in vivo characterization. AAPS Pharm Sci Tech, 2010; 11: 189-96.

[18] Wen HC, Yung KI, Yuh TH, Cheh SW. Statistical Optimization and Stability Study of Quercetin-Loaded Microemulsion. Int J of Pharmacy and Pharmaceutical Sci, 2021, 13 (1) 23-5.

[19] Shravani B, Raghavendra Rao NG. Formulation and evaluation of fast dissolving tablets of montelukast sodium using co-processed superdisintegrants. Int J Drug Dev Res 2014; 6(1):125-4.

[20] Gehel M, Patel M, Amin A, Agrawal R, Dave R, Bariya N. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. AAPS Pharm Sci Tech 2004; 5: e36.